“Best Collaboration” and “Best Technology Application — Upstream” Awards Acknowledges ambr250 mini bioreactor system as an Exceptional Technology
Goettingen, GER | Cambridge, UK - October 27, 2014: Sartorius Stedim Biotech (SSB) today announced that TAP Biosystems, part of SSB Group since 2013, and Merck & Co., Inc. have won two awards at the prestigious 2014 BioProcess International (BPI) Awards. The awards recognize that the ambr250™ mini bioreactor system, developed as a result of this successful partnership, is a major breakthrough in bioprocessing technology.
At the BioProcess International Awards, TAP Biosystems and Merck won the ‘Best Collaboration Award’ beating off stiff competition from other partnerships including Invetech and Janssen. TAP Biosystems and Merck also won the ‘Best Technology Application — Upstream Award’ for the ambr250 automated mini bioreactor system against other excellent products such as the Xcellerex™ XDR-50 MO fermenter system and the MaxCyte® STX™ Scalable Transfection System.
Mwai Ngibuini, ambr250 Product Manager stated: “The main aim of our collaboration with Merck was to develop a simple to set up, single-use mini bioreactor system which has the versatility to replicate traditional bioreactors and fermenters for culturing mammalian and microbial cells. To achieve this we listened carefully to the bioprocessing experts that would use the system, as well as the context into which it would be placed and then worked tirelessly to deliver their vision.”
Ngibuini continued: “We’re delighted to win these awards with Merck because it indicates that the time and effort we all put into this partnership has really been worthwhile and the ambr250 is viewed by our bioprocess peers and experts as breakthrough technology, which has the potential to totally transform process development of antibody and protein-based therapeutics.”
Image Files:
www.sartorius.com/fileadmin/media/global/company/pr_20141024_BPI_award_collaboration.jpg Richard Wales from TAP Biosystems (middle) and Dave Pollard (right) from Merck accept the BPI awards for “Best Collaboration” from BPI editor in chief Anne Montgomery
www.sartorius.com/fileadmin/media/global/company/pr_20141024_BPI_award_application.jpg Mwai Ngibuini from TAP Biosystems (middle) and Dave Pollard (right) from Merck accept the BPI awards for “Best Technology Application — Upstream” from BPI editor in chief Anne Montgomery
www.sartorius.com/fileadmin/media/global/company/pr_20141024_BPI_ambr250.jpg ambr250 mini bioreactor system
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of “turning science into solutions.”
Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,300 people, and in 2013 earned sales revenue of 588.4 million euros.
TAP Biosystems, part of the Sartorius Stedim Biotech Group, is a leading global provider of automated cell culture and fermentation systems for life science research, development and production. TAP’s systems are in use worldwide at pharmaceutical, biotechnology and academic laboratories, supporting bioprocess development and GMP manufacture of biologics and cell therapies, as well as discovery and stem cell research programmes.
About BioProcess International Award The awards celebrate the outstanding achievements, collaborations, business strategies, social corporate responsibility and technology applications that will allow the industry to deliver better, more effective treatments to a global patient base. Organized by BioProcess International (BPI) is a business-to-business publication dedicated to delivering cutting-edge information focused on the development and manufacture of biopharmaceuticals and therapeutics. Learn more at http://www.bioprocessintl.com.
Contacts:
Dominic Grone
Senior Manager Corporate Communications, Sartorius Stedim Biotech
Tel: +49 (0)551.3083324
dominic.grone@sartorius.com
Michaela McAdam,
Marketing Communications Manager, Sartorius Stedim Biotech | TAP Biosystems
Tel: +44 (0) 1763 227200
michaela.mcadam@tapbiosystems.com
